COMPARISON BETWEEN SIMVASTATIN AND BEZAFIBRATE IN EFFECT ON PLASMA LIPOPROTEINS AND APOLIPOPROTEINS IN PRIMARY HYPERCHOLESTEROLAEMIA

COMPARISON BETWEEN SIMVASTATIN AND BEZAFIBRATE IN EFFECT ON PLASMA LIPOPROTEINS AND APOLIPOPROTEINS IN PRIMARY HYPERCHOLESTEROLAEMIA

The ability of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, to lower lipid levels in 16 patients with primary hypercholesterolaemia was compared with that of bezafibrate in a 16-week, double-blind, parallel, placebo-controlled trial that was continued in a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 1988-03, Vol.331 (8586), p.611-613
Hauptverfasser: Schulzeck, P., Jochim, A., Bojanovski, M., Canzler, H., Bojanovski, D.
Format: Artikel
Sprache:eng
Schlagworte:
Cholesterol
Drugs
Side effects
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The ability of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, to lower lipid levels in 16 patients with primary hypercholesterolaemia was compared with that of bezafibrate in a 16-week, double-blind, parallel, placebo-controlled trial that was continued in an open crossover fashion. Simvastatin was better than bezafibrate at lowering total and low-density lipoprotein (LDL)-cholesterol and apolipoprotein B concentrations (30·4% [p
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(88)91414-6